Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...191192193194195196197198199200201...208209»
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    New P4 trial, Metastases:  Apatinib for Advanced Lung Squmamous Carcinoma (clinicaltrials.gov) -  Oct 31, 2018   
    P4,  N=50, Not yet recruiting, 
  • ||||||||||  Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
    Trial completion, Trial completion date:  ESSENCE: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (clinicaltrials.gov) -  Oct 24, 2018   
    P2b,  N=328, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Nov 2018 --> Jul 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jun 2018
  • ||||||||||  HTI-1090 / Jiangsu Hengrui Pharma
    Trial completion date, Trial primary completion date:  A Trial of HTI-1090 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Oct 22, 2018   
    P1,  N=30, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Oct 2018 --> Mar 2019 | Trial primary completion date: Sep 2018 --> Dec 2018
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    New P2 trial:  Study of the Combination of Apatinib and POF (clinicaltrials.gov) -  Oct 15, 2018   
    P2,  N=26, Not yet recruiting, 
  • ||||||||||  AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
    New P1 trial:  Safety, Tolerability and PK of SHR1314 in axSpA (clinicaltrials.gov) -  Oct 12, 2018   
    P1,  N=40, Recruiting, 
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Enrollment closed, Trial initiation date, Trial primary completion date, Metastases:  A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers (clinicaltrials.gov) -  Oct 9, 2018   
    P2,  N=38, Active, not recruiting, 
    Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Initiation date: May 2017 --> Dec 2016 | Trial primary completion date: Oct 2018 --> Jul 2018
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment change, Trial completion date, Trial primary completion date:  SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) -  Oct 1, 2018   
    P1/2,  N=150, Recruiting, 
    Recruiting --> Active, not recruiting | Initiation date: May 2017 --> Dec 2016 | Trial primary completion date: Oct 2018 --> Jul 2018 N=40 --> 150 | Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Aug 2018 --> Aug 2019
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment open, Trial completion date, Trial primary completion date:  Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma (clinicaltrials.gov) -  Sep 28, 2018   
    P2,  N=50, Recruiting, 
    N=40 --> 150 | Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Aug 2018 --> Aug 2019 Not yet recruiting --> Recruiting | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jul 2018 --> Aug 2019
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Trial completion date, Metastases:  A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck (clinicaltrials.gov) -  Sep 26, 2018   
    P2,  N=68, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jul 2018 --> Aug 2019 Trial completion date: May 2018 --> Dec 2018
  • ||||||||||  AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Trial completion date, Trial primary completion date:  A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer (clinicaltrials.gov) -  Sep 24, 2018   
    P1,  N=51, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Sep 2018 --> Sep 2020 | Trial primary completion date: Jun 2018 --> Jun 2020
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Phase classification, Trial completion date, Trial primary completion date:  ATinPC: Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov) -  Sep 19, 2018   
    P2,  N=30, Not yet recruiting, 
    Trial completion date: Sep 2018 --> Sep 2020 | Trial primary completion date: Jun 2018 --> Jun 2020 Phase classification: P3 --> P2 | Trial completion date: Mar 2020 --> Aug 2020 | Trial primary completion date: Sep 2019 --> Mar 2020
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Phase classification:  ATinPC: Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov) -  Sep 18, 2018   
    P3,  N=30, Not yet recruiting, 
    Phase classification: P3 --> P2 | Trial completion date: Mar 2020 --> Aug 2020 | Trial primary completion date: Sep 2019 --> Mar 2020 Phase classification: P=N/A --> P3
  • ||||||||||  plinabulin (BPI 2358) / BeyondSpring
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  PROTECTIVE-2: Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia (clinicaltrials.gov) -  Sep 12, 2018   
    P2/3,  N=237, Active, not recruiting, 
    Phase classification: P=N/A --> P3 Recruiting --> Active, not recruiting | N=180 --> 237 | Trial completion date: Dec 2018 --> Apr 2019 | Trial primary completion date: Jul 2018 --> Oct 2018